- Home
- WRBY vs SLNO Comparison
WRBY vs SLNO Comparison
Compare WRBY & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- SLNO
- Stock Information
- Founded
- WRBY 2010
- SLNO 1999
- Country
- WRBY United States
- SLNO United States
- Employees
- WRBY N/A
- SLNO N/A
- Industry
- WRBY Ophthalmic Goods
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- WRBY Health Care
- SLNO Health Care
- Exchange
- WRBY Nasdaq
- SLNO Nasdaq
- Market Cap
- WRBY 2.9B
- SLNO 1.9B
- IPO Year
- WRBY 2021
- SLNO 2014
- Fundamental
- Price
- WRBY $25.36
- SLNO $45.71
- Analyst Decision
- WRBY Buy
- SLNO Strong Buy
- Analyst Count
- WRBY 10
- SLNO 6
- Target Price
- WRBY $21.00
- SLNO $74.83
- AVG Volume (30 Days)
- WRBY 1.6M
- SLNO 613.7K
- Earning Date
- WRBY 02-26-2025
- SLNO 11-06-2024
- Dividend Yield
- WRBY N/A
- SLNO N/A
- EPS Growth
- WRBY N/A
- SLNO N/A
- EPS
- WRBY N/A
- SLNO N/A
- Revenue
- WRBY $742,527,000.00
- SLNO N/A
- Revenue This Year
- WRBY $16.87
- SLNO N/A
- Revenue Next Year
- WRBY $13.10
- SLNO N/A
- P/E Ratio
- WRBY N/A
- SLNO N/A
- Revenue Growth
- WRBY 13.47
- SLNO N/A
- 52 Week Low
- WRBY $11.35
- SLNO $35.70
- 52 Week High
- WRBY $25.89
- SLNO $60.92
- Technical
- Relative Strength Index (RSI)
- WRBY 64.03
- SLNO 40.89
- Support Level
- WRBY $23.76
- SLNO $43.84
- Resistance Level
- WRBY $25.89
- SLNO $47.14
- Average True Range (ATR)
- WRBY 1.01
- SLNO 2.13
- MACD
- WRBY -0.12
- SLNO 0.13
- Stochastic Oscillator
- WRBY 79.77
- SLNO 43.85
About WRBY Warby Parker Inc.
Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts, and providing the facility of eye exams and vision tests. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.